Acasti Announces Review Process of Strategic Alternatives
September 29 2020 - 6:55AM
Acasti Pharma Inc. (“
Acasti” or the
“
Company”) (NASDAQ: ACST – TSX-V: ACST) announces
the Company has commenced a formal process to explore and evaluate
strategic alternatives to enhance shareholder value. Towards this
end, the Company has engaged Oppenheimer & Co., Inc., as its
financial advisor to assist in the process. There can be no
assurance of a successful outcome from these efforts, or of the
form or timing of any such outcome. The Company does not intend to
make any further disclosures regarding the strategic review process
unless and until a specific course of action is approved by the
Company’s Board of Directors.
In the meantime, the Company and its clinical
advisors plan to complete the full data analyses as contemplated in
the Statistical Analysis Plan for TRILOGY 2, including the
secondary and exploratory endpoints, and the pooling of the data
from TRILOGY 1 and 2.
Forward Looking Statements
Statements in this press release that are not
statements of historical or current fact constitute
“forward-looking information” within the meaning of Canadian
securities laws and “forward-looking statements” within the meaning
of U.S. federal securities laws (collectively, “forward-looking
statements”). Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could
cause the actual results of Acasti to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements labeled with the terms “believes,” “belief,”
“expects,” “intends,” “anticipates,” “potential,” “should,” “may,”
“will,” “plans,” “continue”, “targeted” or other similar
expressions to be uncertain and forward-looking. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Forward-looking statements in this press release include, but are
not limited to, information or statements about Acasti’s strategy,
future operations, its review of strategic options, potential value
for CaPre®, prospects and the plans of management.
The forward-looking statements contained in this
press release are expressly qualified in their entirety by this
cautionary statement, the “Special Note Regarding Forward-Looking
Statements” section contained in Acasti’s latest annual report on
Form 10-K, which will be available on EDGAR
at www.sec.gov/edgar/shtml, on SEDAR
at www.sedar.com and on the investor section of Acasti’s
website at www.acastipharma.com. All forward-looking
statements in this press release are made as of the date of this
press release. Acasti does not undertake to update any such
forward-looking statements whether as a result of new information,
future events or otherwise, except as required by law. The
forward-looking statements contained herein are also subject
generally to assumptions and risks and uncertainties that are
described from time to time in Acasti’s public securities filings
with the Securities and Exchange Commission and the Canadian
securities commissions, including Acasti’s latest annual report on
Form 10-K under the caption “Risk Factors”.
Neither NASDAQ, the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Acasti
Contact:Jan
D’AlviseChief Executive OfficerTel: 450-686-4555Email:
info@acastipharma.comwww.acastipharma.com
Investor
Contact:Crescendo
Communications, LLCTel: 212-671-1020Email:
ACST@crescendo-ir.com
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Apr 2023 to Apr 2024